Precision Biosciences (DTIL) Debt to Equity (2021 - 2025)
Precision Biosciences (DTIL) has disclosed Debt to Equity for 4 consecutive years, with $1.35 as the latest value for Q3 2025.
- On a quarterly basis, Debt to Equity rose 291.64% to $1.35 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.35, a 291.64% increase, with the full-year FY2024 number at $0.4, down 66.69% from a year prior.
- Debt to Equity was $1.35 for Q3 2025 at Precision Biosciences, up from $0.66 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.35 in Q3 2025 to a low of $0.02 in Q2 2021.
- A 4-year average of $0.56 and a median of $0.53 in 2025 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: tumbled 66.69% in 2024, then soared 291.64% in 2025.
- Precision Biosciences' Debt to Equity stood at $0.02 in 2021, then soared by 4812.06% to $1.19 in 2023, then tumbled by 66.69% to $0.4 in 2024, then soared by 239.83% to $1.35 in 2025.
- Per Business Quant, the three most recent readings for DTIL's Debt to Equity are $1.35 (Q3 2025), $0.66 (Q2 2025), and $0.45 (Q1 2025).